The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease. ⋯ As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 [ClinicalTrials.gov].).
-
Multicenter Study Controlled Clinical Trial
Advanced life support for out-of-hospital respiratory distress.
Respiratory distress is a common symptom of patients transported to hospitals by emergency medical services (EMS) personnel. The benefit of advanced life support for such patients has not been established. ⋯ The addition of a specific regimen of out-of-hospital advanced-life-support interventions to an existing EMS system that provides basic life support was associated with a decrease in the rate of death of 1.9 percentage points among patients with respiratory distress.
-
Interactive Tutorial
Videos in clinical medicine. Central venous catheterization.